Interleukin-17 (IL-17) is a pro-inflammatory cytokine that contributes to the pathogenesis of several inflammatory diseases.
The key IL-17 family members are IL-17A and IL-17F, which share a 50% sequence homology. They bind to an IL-17 receptor (IL-17R) complex that is composed of two chains, known as IL-17RA and IL-17RC. IL-17A and IL-17F interact with inflammatory cytokines such as IL-1 and tumour necrosis factor, often in a synergistic manner.
IL-17A and IL-17F are the key cytokines produced by T helper 17 (TH17) cells. These cells are crucial for the control of infections, especially extracellular bacterial and fungal infections. They also contribute to epithelial and mucosal protection.
Overexpression of IL-17 and TH17 cells contributes to tissue inflammation that is accompanied by matrix destruction, autoimmunity and vascular activation.
Positive results have been obtained in clinical trials with two monoclonal antibodies against IL-17A in psoriasis, rheumatoid arthritis and ankylosing spondylitis. Positive results in a clinical trial in psoriasis have been obtained with a monoclonal antibody targeting IL-17RA.
Dual inhibitors of IL-17A and IL-17F, of IL-17A and tumour necrosis factor as well as inhibitors of IL-17R signalling are at the preclinical stage of development.
The key role of interleukin-17 (IL-17) and T helper 17 (TH17) cells in tissue inflammation, autoimmunity and host defence led to the experimental targeting of these molecules in mouse models of diseases as well as in clinical settings. Moreover, the demonstration that IL-17 and TH17 cells contribute to local and systemic aspects of disease pathogenesis, as well as the finding that the IL-17–TH17 cell pathway is regulated by IL-23, prompted the identification of inhibitors. These inhibitors include biotechnology products that target IL-23 as well as the leading member of the IL-17 family, IL-17A, and one of its receptors, IL-17 receptor A. Several clinical trials of these inhibitors are underway, and positive results have been obtained in psoriasis, rheumatoid arthritis and ankylosing spondylitis. This Review focuses on the current knowledge of the IL-17–TH17 cell pathway to better understand the positive as well as potential negative consequences of targeting them.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Hashimoto’s thyroiditis increases the risk of new-onset systemic lupus erythematosus: a nationwide population-based cohort study
Arthritis Research & Therapy Open Access 09 February 2023
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Molecular Cancer Open Access 26 September 2022
Cathepsin K regulates the tumor growth and metastasis by IL-17/CTSK/EMT axis and mediates M2 macrophage polarization in castration-resistant prostate cancer
Cell Death & Disease Open Access 22 September 2022
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Yao, Z. et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155, 5483–5486 (1995). This is the first paper to describe IL-17.
Fossiez, F. et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183, 2593–2603 (1996). This early study describes the role of IL-17 in inflammation.
Rouvier, E., Luciani, M. F., Mattei, M. G., Denizot, F. & Golstein, P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 150, 5445–5456 (1993).
Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123–1132 (2005). This is one of the first papers to highlight the T H 17 subset of T cells in mice.
Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunol. 6, 1133–1141 (2005).
Bettelli, E., Korn, T. & Kuchroo, V. K. Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol. 19, 652–657 (2007).
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M. & Murphy, K. M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24, 677–688 (2006).
Miossec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888–898 (2009). This is a review on the clinical aspects of IL-17 and T H 17 cells.
Chabaud, M. et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42, 963–970 (1999). This is the first paper to describe the production of functional IL-17 in chronic inflammation.
Zrioual, S. et al. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J. Immunol. 182, 3112–3120 (2009).
Aggarwal, S. & Gurney, A. L. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 71, 1–8 (2002).
Hymowitz, S. G. et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 20, 5332–5341 (2001).
Wright, J. F. et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J. Biol. Chem. 282, 13447–13455 (2007).
Yang, X. O. et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205, 1063–1075 (2008).
Chang, S. H. et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35, 611–621 (2011).
Wang, Y. H. et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J. Exp. Med. 204, 1837–1847 (2007).
Kleinschek, M. A. et al. IL-25 regulates Th17 function in autoimmune inflammation. J. Exp. Med. 204, 161–170 (2007).
Yao, Z. et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3, 811–821 (1995).
Yao, Z. et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9, 794–800 (1997).
Toy, D. et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 177, 36–39 (2006).
Ely, L. K., Fischer, S. & Garcia, K. C. Structural basis of receptor sharing by interleukin 17 cytokines. Nature Immunol. 10, 1245–1251 (2009).
Rong, Z. et al. IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling. Cell Res. 19, 208–215 (2009).
Song, X. et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nature Immunol. 12, 1151–1158 (2011).
Ramirez-Carrozzi, V. et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nature Immunol. 12, 1159–1166 (2011).
Chang, S. H., Park, H. & Dong, C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J. Biol. Chem. 281, 35603–35607 (2006).
Qian, Y. et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nature Immunol. 8, 247–256 (2007).
Hot, A. & Miossec, P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann. Rheum. Dis. 70, 727–732 (2011).
Henness, S. et al. IL-17A augments TNF-α-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability. J. Allergy Clin. Immunol. 114, 958–964 (2004).
Hartupee, J., Liu, C., Novotny, M., Li, X. & Hamilton, T. IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 179, 4135–4141 (2007).
Shen, F., Hu, Z., Goswami, J. & Gaffen, S. L. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J. Biol. Chem. 281, 24138–24148 (2006).
Shi, P. et al. Persistent stimulation with interleukin-17 desensitizes cells through SCFβ-TrCP-mediated degradation of Act1. Sci. Signal. 4, ra73 (2011).
Zhu, S. et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J. Exp. Med. 207, 2647–2662 (2010).
Liu, C. et al. A CC′ loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation. Sci. Signal. 4, ra72 (2011).
Kramer, J. M. et al. Evidence for ligand-independent multimerization of the IL-17 receptor. J. Immunol. 176, 711–715 (2006).
Infante-Duarte, C., Horton, H. F., Byrne, M. C. & Kamradt, T. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165, 6107–6115 (2000).
Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 (2003).
Happel, K. I. et al. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. 170, 4432–4436 (2003).
Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003).
Langrish, C. L. et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202, 96–105 (2004).
Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005).
Mangan, P. R. et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 441, 231–234 (2006).
Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006). This study shows the balance between T H 17 cells and regulatory T cells in immunopathology.
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. & Stockinger, B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179–189 (2006).
Yang, X. O. et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282, 9358–9363 (2007).
Dong, C. Genetic controls of Th17 cell differentiation and plasticity. Exp. Mol. Med. 43, 1–6 (2011).
Sutton, C. E. et al. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 331–341 (2009).
Martin, B., Hirota, K., Cua, D. J., Stockinger, B. & Veldhoen, M. Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity 31, 321–330 (2009).
Chung, Y. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30, 576–587 (2009).
Awasthi, A. et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nature Immunol. 8, 1380–1389 (2007).
Ghoreschi, K. et al. Generation of pathogenic TH17 cells in the absence of TGF-β signalling. Nature 467, 967–971 (2010).
Lockhart, E., Green, A. M. & Flynn, J. L. IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J. Immunol. 177, 4662–4669 (2006).
Shibata, K., Yamada, H., Hara, H., Kishihara, K. & Yoshikai, Y. Resident Vδ1+ γδ T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J. Immunol. 178, 4466–4472 (2007).
Michel, M. L. et al. Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204, 995–1001 (2007).
Pichavant, M. et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J. Exp. Med. 205, 385–393 (2008).
Milpied, P. et al. IL-17-producing invariant NKT cells in lymphoid organs are recent thymic emigrants identified by neuropilin-1 expression. Blood 118, 2993–3002 (2011).
Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: the sentinels of the immune system. Nature Rev. Immunol. 10, 479–489 (2010).
Ikeda, K. et al. Mast cells produce interleukin-25 upon FcɛRI-mediated activation. Blood 101, 3594–3596 (2003).
Mrabet-Dahbi, S., Metz, M., Dudeck, A., Zuberbier, T. & Maurer, M. Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Exp. Dermatol. 18, 437–444 (2009).
Lin, A. M. et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187, 490–500 (2011).
Hueber, A. J. et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J. Immunol. 184, 3336–3340 (2010).
Moran, E. M. et al. IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS ONE 6, e24048 (2011).
Noordenbos, T. et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 64, 99–109 (2012).
Fiala, M. et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J. Neuroinflamm. 7, 76 (2010).
Ge, D. & You, Z. Expression of interleukin-17RC protein in normal human tissues. Int. Arch. Med. 1, 19 (2008).
Lubberts, E. et al. Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J. Immunol. 175, 3360–3368 (2005).
Miossec, P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. 48, 594–601 (2003).
Koenders, M. I. et al. Tumor necrosis factor–interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum. 63, 2329–2339 (2011).
van Hamburg, J. P. et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum. 63, 73–83 (2011).
Eljaafari, A. et al. Bone marrow- and synovium-derived mesenchymal cells promote Th-17 cells through caspase-1 activation: contribution to rheumatoid arthritis chronicity. Arthritis Rheum. 64, 2147–2157 (2012).
Chabaud, M. & Miossec, P. The combination of tumor necrosis factor α blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 44, 1293–1303 (2001).
Hsu, H. C. et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nature Immunol. 9, 166–175 (2008).
Toh, M. L. et al. Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS ONE 5, e13416 (2010).
Chabaud, M., Fossiez, F., Taupin, J. L. & Miossec, P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J. Immunol. 161, 409–414 (1998).
Schwarzenberger, P. et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J. Immunol. 161, 6383–6389 (1998).
Schwarzenberger, P. et al. Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J. Immunol. 164, 4783–4789 (2000).
McAleer, J. P. & Kolls, J. K. Mechanisms controlling Th17 cytokine expression and host defense. J. Leukoc. Biol. 90, 263–270 (2011).
Ye, P. et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194, 519–527 (2001).
Forlow, S. B. et al. Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice. Blood 98, 3309–3314 (2001).
Stark, M. A. et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22, 285–294 (2005).
Kolls, J. K., McCray, P. B. Jr & Chan, Y. R. Cytokine-mediated regulation of antimicrobial proteins. Nature Rev. Immunol. 8, 829–835 (2008). This is a review on the role of IL-17 in antimicrobial host defence.
Huang, W., Na, L., Fidel, P. L. & Schwarzenberger, P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J. Infect. Dis. 190, 624–631 (2004).
Conti, H. R. et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206, 299–311 (2009).
Schwarzenberger, P. & Kolls, J. K. Interleukin 17: an example for gene therapy as a tool to study cytokine mediated regulation of hematopoiesis. J. Cell Biochem. 85 (Suppl. 38), 88–95 (2002).
Ishigame, H. et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30, 108–119 (2009).
Cho, J. S. et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 120, 1762–1773 (2010).
Rudner, X. L., Happel, K. I., Young, E. A. & Shellito, J. E. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect. Immun. 75, 3055–3061 (2007).
Wuthrich, M. et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J. Clin. Invest. 121, 554–568 (2011).
Puel, A. et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65–68 (2011).
Zelante, T. et al. Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nature Commun. 3, 683 (2012).
Aujla, S. J. et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nature Med. 14, 275–281 (2008).
Cooper, A. M. & Khader, S. A. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol. Rev. 226, 191–204 (2008).
Lin, Y. et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31, 799–810 (2009).
Khader, S. A. et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nature Immunol. 8, 369–377 (2007).
Lubberts, E. et al. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm. Res. 51, 102–104 (2002).
Lubberts, E. et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50, 650–659 (2004).
Koenders, M. I. et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 52, 3239–3247 (2005).
Koenders, M. I. et al. Interleukin-17 acts independently of TNF-α under arthritic conditions. J. Immunol. 176, 6262–6269 (2006).
Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356, 580–592 (2007).
Capon, F. et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122, 201–206 (2007).
Zheng, Y. et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648–651 (2007).
Zaba, L. C. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183–3194 (2007).
Kryczek, I. et al. Induction of IL-17+ T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J. Immunol. 181, 4733–4741 (2008).
Lowes, M. A. et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128, 1207–1211 (2008).
Pene, J. et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J. Immunol. 180, 7423–7430 (2008).
Harper, E. G. et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J. Invest. Dermatol. 129, 2175–2183 (2009).
Appel, H. et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res. Ther. 13, R95 (2011).
Fisher, S. A. et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genet. 40, 710–712 (2008).
Dubinsky, M. C. et al. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm. Bowel Dis. 13, 511–515 (2007).
Kobayashi, T. et al. IL-23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57, 1682–1689 (2008).
Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310–1316 (2006).
Elson, C. O. et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132, 2359–2370 (2007).
O'Connor, W. Jr et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nature Immunol. 10, 603–609 (2009).
Marotte, H., Charrin, J. E. & Miossec, P. Infliximab-induced aseptic meningitis. Lancet 358, 1784 (2001).
Fromont, A., De Seze, J., Fleury, M. C., Maillefert, J. F. & Moreau, T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45, 55–57 (2009).
Ifergan, I. et al. The blood–brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 131, 785–799 (2008).
Uyttenhove, C. & Van Snick, J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol. 36, 2868–2874 (2006).
Lock, C. et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature Med. 8, 500–508 (2002).
Naranjo, A. et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res. Ther. 10, R30 (2008).
Roman, M. J. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399–2406 (2003).
Greenberg, J. D. et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 576–582 (2011).
Hot, A., Lenief, V. & Miossec, P. Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann. Rheum. Dis. 71, 768–776 (2012).
Marder, W. et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann. Rheum. Dis. 70, 1550–1555 (2011).
Hashmi, S. & Zeng, Q. T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron. Artery Dis. 17, 699–706 (2006).
Eid, R. E. et al. Interleukin-17 and interferon-γ are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119, 1424–1432 (2009).
van Es, T. et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem. Biophys. Res. Commun. 388, 261–265 (2009).
Smith, E. et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121, 1746–1755 (2010).
Chen, S. et al. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J. Immunol. 185, 5619–5627 (2010).
McAllister, F. et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-α and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J. Immunol. 175, 404–412 (2005).
Ivanov, S., Palmberg, L., Venge, P., Larsson, K. & Linden, A. Interleukin-17A mRNA and protein expression within cells from the human bronchoalveolar space after exposure to organic dust. Respir. Res. 6, 44 (2005).
Bullens, D. M. et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir. Res. 7, 135 (2006).
McKinley, L. et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 181, 4089–4097 (2008).
Lajoie, S. et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nature Immunol. 11, 928–935 (2010).
Al-Ramli, W. et al. TH17-associated cytokines (IL-17A and IL-17F) in severe asthma. J. Allergy Clin. Immunol. 123, 1185–1187 (2009).
Tan, H. L. et al. The Th17 pathway in cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 184, 252–258 (2011).
Chen, K. et al. IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke. PLoS ONE 6, e20333 (2011).
Di Stefano, A. et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin. Exp. Immunol. 157, 316–324 (2009).
Doe, C. et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 138, 1140–1147 (2010).
Chang, Y. et al. CD8 positive T cells express IL-17 in patients with chronic obstructive pulmonary disease. Respir. Res. 12, 43 (2011).
Chu, S. et al. The expression of Foxp3 and ROR gamma t in lung tissues from normal smokers and chronic obstructive pulmonary disease patients. Int. Immunopharmacol. 11, 1780–1788 (2011).
Shan, M. et al. Cigarette smoke induction of osteopontin (SPP1) mediates TH17 inflammation in human and experimental emphysema. Sci. Transl. Med. 4, 117ra119 (2012).
Simonian, P. L. et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J. Immunol. 182, 657–665 (2009).
Joshi, A. D. et al. Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 179, 705–716 (2009).
Wilson, M. S. et al. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207, 535–552 (2010).
Mi, S. et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-β1-dependent and -independent mechanisms. J. Immunol. 187, 3003–3014 (2011).
Wong, C. K. et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 127, 385–393 (2008).
Tartour, E. et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 59, 3698–3704 (1999).
Chevrel, G. et al. Interleukin-17 increases the effects of IL-1β on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J. Neuroimmunol. 137, 125–133 (2003).
Abdulahad, W. H., Stegeman, C. A., Limburg, P. C. & Kallenberg, C. G. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 58, 2196–2205 (2008).
Zou, W. & Restifo, N. P. TH17 cells in tumour immunity and immunotherapy. Nature Rev. Immunol. 10, 248–256 (2010).
Garber, K. Newsmaker: lycera. Nature Biotech. 29, 679 (2011).
Huh, J. R. et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 472, 486–490 (2011).
Solt, L. A. et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472, 491–494 (2011).
Xu, T. et al. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORγ t protein. J. Biol. Chem. 286, 22707–22710 (2011).
Haylock-Jacobs, S. et al. PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J. Autoimmun. 36, 278–287 (2011).
Dhimolea, E. & Reichert, J. M. World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA. MAbs 4, 4–13 (2012).
Spriggs, M. K. Interleukin-17 and its receptor. J. Clin. Immunol. 17, 366–369 (1997).
Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nature Rev. Immunol. 9, 556–567 (2009).
Zrioual, S. et al. IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J. Immunol. 180, 655–663 (2008).
Samson, M. et al. Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum. 64, 2499–2503 (2012).
Hueber, W. et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 (2010). This study describes the clinical effects of an IL-17A-targeted antibody in three inflammatory disorders.
Baeten, D. et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 62, Abstract L3847 (2010).
Genovese, M. C. et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929–939 (2010). This paper is the first to report on a clinical trial in which IL-17A was targeted.
Papp, K. A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181–1189 (2012). This is the first paper to demonstrate the targeting of IL-17RA.
Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 17 May 2012 (doi:10.1136/gutjnl-2011-301668).
Symons, A., Budelsky, A. L. & Towne, J. E. Are Th17 cells in the gut pathogenic or protective? Mucosal Immunol. 5, 4–6 (2012).
Kolls, J. K., Kanaly, S. T. & Ramsay, A. J. Interleukin-17: an emerging role in lung inflammation. Am. J. Respir. Cell Mol. Biol. 28, 9–11 (2003).
Leonardi, C. et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366, 1190–1199 (2012).
Miossec, P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum. 56, 2111–2115 (2007).
P.M.'s work is supported by grants from the Institut Mérieux, the Hospices Civils de Lyon (HCL) and the Institut Universitaire de France (IUF). J.K.K.'s work was supported by the National Heart, Lung, and Blood Institute (NHBLI) grant R37-HL079142.
The authors declare no competing financial interests.
Abbott 2011 Annual Report (Financial Review: Part 4)
- T helper 17 cells
(TH17 cells). A lineage of CD4+ T cells that are defined by the expression of interleukin-17A (IL-17A) and IL-17F; the development of these cells is controlled by the transcription factors retinoid-related orphan receptor-α (RORA) and RORC.
- Cystine knots
Motifs that were first described in nerve growth factor, wherein two disulphide bridges are formed from paired cysteine molecules. This motif conveys protein stability.
- CCAAT/enhancer-binding proteins
(C/EBPs). A family of transcription factors that regulate gene expression by interacting with the CCAAT box motif.
- CC′ loop region
A region of the cytoplasmic SEFIR domain (named after SEF and a homologous TIR (Toll/IL-1R) domain) of interleukin-17 (IL-17) receptor, defined by the third strand (C) and the third helix (C′).
- Memory CD4+ T cells
A putative subpopulation of relatively long-lived CD4+ T cells that have interacted with their cognate antigen.
- TH1-associated diseases
Diseases attributed to interferon-γ (IFNγ)-producing CD4+ T cells.
Signal transducer and activator of transcription 4; a member of the STAT protein family that is required for the development of T helper 1 (TH1) CD4+ T cells.
Signal transducer and activator of transcription 6; a member of the STAT protein family that is required for the development of T helper 2 (TH2) CD4+ T cells.
- Naive T cells
T cells that have not interacted with their cognate antigen.
Retinoid-related orphan receptor-γ. RORC encodes a transcription factor that is expressed in interleukin-17 (IL-17)-producing cells.
- γδ T cells
A subset of T cells that express a T cell receptor consisting of a γ- and δ-chain as opposed to an α- and β-chain. These cells are enriched at mucosal surfaces: for example, in the gastrointestinal tract, skin and lung.
- Invariant NK cells
(iNK cells). A subset of natural killer (NK) cells that express an invariant T cell receptor.
- Fcɛ receptor I
A protein that serves as the high-affinity receptor for immunoglobulin E.
- TH2-type responses
Immune responses associated with the T helper 2 (TH2) subset of CD4+ T cells, such as allergy or immune responses to helminth infection.
- Acute phase response
An increase in levels of plasma proteins in response to acute inflammation.
- Matrix metalloproteinases
A family of zinc-dependent proteases that can degrade extracellular matrix proteins.
- Receptor activator of NF-κB ligand
(RANKL). A member of the tumour necrosis factor superfamily expressed on osteoblasts that can activate osteoclasts to mediate bone resorption.
- B cells
A subpopulation of lymphocytes that develop in the bone marrow and mediate humoral (that is, antibody-mediated) immunity.
- TNF receptor 2
Tumour necrosis factor (TNF) receptor 2 (TNFR2; also known as p75 or TNFRSF1B); a 75 kDa receptor that can bind to TNF and lymphotoxin-α.
An increased density of neutrophils in peripheral blood.
- Mucosal immunity
Immune responses that occur at mucosal membranes.
- Apoe−/− mice
Mice with a homozygous deletion in the apolipoprotein E (Apoe) gene; these mice are a model of hypercholesterolaemia.
- ACR20 response rate
The response rate of patients in clinical trials for rheumatoid arthritis who show a 20% decrease in the clinical American College of Rheumatology (ACR) score.
Rights and permissions
About this article
Cite this article
Miossec, P., Kolls, J. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11, 763–776 (2012). https://doi.org/10.1038/nrd3794
This article is cited by
Hashimoto’s thyroiditis increases the risk of new-onset systemic lupus erythematosus: a nationwide population-based cohort study
Arthritis Research & Therapy (2023)
The star target in SLE: IL-17
Inflammation Research (2023)
Synoviocytes and skin fibroblasts show opposite effects on IL-23 production and IL-23 receptor expression during cell interactions with immune cells
Arthritis Research & Therapy (2022)
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Molecular Cancer (2022)
Single-cell transcriptomics reveals immune dysregulation mediated by IL-17A in initiation of chronic lung injuries upon real-ambient particulate matter exposure
Particle and Fibre Toxicology (2022)